Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis.
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis.
Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis.
[Cognitive impairment in demyelinating disease].
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
Assessment of cerebral venous return by a novel plethysmography method.
Corticosteroids for treating optic neuritis.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Incidence of multiple sclerosis in Northern Lisbon, Portugal: 1998¿2007.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research.
Vitamin D3 Receptor ( VDR ) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?

Pages